Vertex Pharmaceuticals Inc. closed $111.56 below its 52-week high ($519.88), which the company achieved on November 8th.
Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...
Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.
Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 20 years ago, it would be worth $39,441.77 today based on ...
Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell ...
Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with ...
The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.
The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...
Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...
CWA Asset Management Group LLC trimmed its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) ...
Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...
周二，RBC Capital Markets调整了Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)的目标价，从之前的400美元略微上调至401美元。该公司维持对这家生物科技公司股票的"行业表现"评级，目前股价为404.07美元。根据 InvestingPro 分析，该股票的交易价格略高于其公允价值，分析师目标价范围在325美元至602美元之间。
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback